Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Development of a modified hard gelatin capsule for colon-targeted drug delivery of hydrogel-based piroxicam microparticles

Calister E Ugwu , Chukwuma O Agubata, Salome A Chime, Nicholas C Obitte, Ikechukwu V Onyishi, Godswill C Onunkwo, Sabinus I Ofoefule, Amarauche Chukwu

Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Nigeria;

For correspondence:- Calister Ugwu Email: calister.ugwu@unn.edu.ng Tel:+2348038933463

Accepted: 12 October 2022 Published: 30 November 2022

Citation: Ugwu CE, Agubata CO, Chime SA, Obitte NC, Onyishi IV, Onunkwo GC, et al. Development of a modified hard gelatin capsule for colon-targeted drug delivery of hydrogel-based piroxicam microparticles. Trop J Pharm Res 2022; 21(11):2285-2293 doi: 10.4314/tjpr.v21i11.3

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop modified hard gelatin capsules (MHGCs) for colon-specific delivery of hydrogel-based piroxicam microparticles.

Methods: Solvent evaporation technique was adopted for the microencapsulation of piroxicam using liquid paraffin (PL.MPs) and soybean oil (PS.MPs) which were subsequently encapsulated in MHGCs (water-impervious). Anti-inflammatory and in vitro dissolution studies were conducted on the unencapsulated microparticles (MPs). Furthermore, in vitro colon-specific sequential drug release from impervious capsules was carried out for 2 h at pH 1.2 and 3 h in 6.8, and ≥ 5 h in 7.4, to simulate drug release in the stomach, small intestine, and colon environment, respectively. Differential scanning calorimetry (DSC) analysis was also conducted on the formulations.

Results: Edema inhibition of PL.MPs and PS.MPs were within the range of 51.0 – 64.0 and 58.0 – 69.0 %, respectively. In vitro colon-specific drug dissolution studies revealed absence, minimal, and highest amounts of drug release from MHGCs in pH 1.2, 6.8 and 7.4 media, respectively. Decreased crystallinity of the microparticles was indicated by a broad endothermic peak.

Conclusion: The MHGCs hold promise as a potential alternative delivery system for hydrogel-based piroxicam microparticles designed for colon-targeted drug delivery. However, clinical development studies are required.

Keywords: Modified hard gelatin capsules, microparticles, HPMC acetate succinate, anti-inflammation